Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jul 02, 2022 6:18pm
237 Views
Post# 34797641

RE:Because of a lack of better treatments...

RE:Because of a lack of better treatments...

wildbird1 wrote: Question?
Why keytruda that has a a very low 18%CR and many serious side effects, was accepted by the FDA for Bladder Cancer patients.

In this article dated Jan.10, 2020..
https://gr-cis.com/2020/01/10/mercks-keytruda-approved-for-high-risk-bladder-cancer/ .
Paragraph 5,
Merck said" Keytruda will be a new clinical option for a patients population that previously had limited FDA- Approved therapies available".

Can you believe this... Keytruda with its very low CR% and serious side effects was approved by the FDA for Bladder cancer, because of a lack of better treatments.

TLT time is coming.







Hi wildbird1...

Fortunately for us (unfortunately for patients), the options that are FDA approved are limited to only two...1) Systemically administered Keytruda & 2) Intravesical Valrubicin...both significant underperformers.  If our results pan out, we are certainly well-positioned in the front of a very short line to be the new best single-agent option.

Historically, there is a superior treatment protocol to Keytruda that is currently being used by some urologists for both BCG-unresponsive NMIBC & BCG-naive NMIBC.  The protocol, however, has yet to be FDA approved.  The above treatment is an intravesical option that utilizes two chemotherapeutic drugs, gemcitabine + docetaxel.  The protocol has seen an increase in recent use due to not only its superior historical efficacy, but also b/o the recent BCG supply shortages.  

The big drawback of the above non-FDA approved option is the fact that it's a very treatment-intensive protocol that includes 6 weekly induction treatments followed by monthly maintenance treatments for up to 2 years for responders.  Such a treatment-intensive protocol can obviously be a burden on patients, but it can also disrupt the general workflow in the treating clinic (due to limited clinic space).  A recent survey amongst urologists also noted challenges in getting the drugs supplied from hospital pharmacies.   

There are a lot of moving parts (including non-FDA approved) in the world of BCG-unresponsive NMIBC.  With the right partner, navigating this evolving biotech maze & getting from bench to clinic should be a lot easier.  Having a first-mover advantage for our tech shouldn't hurt either : ).  As you noted, despite some treatment gains made periodically, there are still too few FDA-approved options that can adequately forestall the need for cystectomy...& perhaps equally important, there are currently no options (FDA or non-FDA approved) that are both treatment & patient-friendly.

I agree...TLT time is on the horizon, & the lights of Vegas are getting brighter.  All imo.  Good luck...

<< Previous
Bullboard Posts
Next >>